AYTU BioPharma, Inc. - AYTU STOCK NEWS

Aytu BioPharma (Nasdaq: AYTU) has announced its participation in the upcoming Sidoti Micro-Cap Virtual Conference on August 14-15, 2024. The company's CEO, Josh Disbrow, will deliver a webcasted presentation on Thursday, August 15, at 12:15 p.m. Eastern time. This fireside chat will be accessible through Aytu's investor relations website and will remain available for replay after the event.

In addition to the presentation, Aytu's management team will engage in one-on-one meetings with investors throughout the conference. Interested parties can arrange meetings through their Sidoti representatives or by contacting Aytu's investor relations team directly. This event provides an opportunity for investors to gain insights into Aytu BioPharma, a pharmaceutical company focused on commercializing novel therapeutics.

Aytu BioPharma (Nasdaq: AYTU) has announced the sale of its Consumer Health business following a strategic wind down of operations. The divestiture includes the e-commerce platform, inventory, consumer brands, intellectual property, contracts, and liabilities. Aytu will receive revenue-based royalty payments on future sales of former Consumer Health products.

The move aligns with Aytu's strategy to focus on its prescription pharmaceutical business and achieve consistent profitability. The company expects this strategic shift, along with the closure of its Grand Prairie, Texas manufacturing site, to significantly enhance operating results and drive stockholder value. The Consumer Health business had been operating at near adjusted EBITDA breakeven during the wind down period.

Aytu BioPharma has refinanced its existing term loan and extended its revolving credit facility on more favorable terms. The company received $3.5 million by exercising warrants and used part of this to reduce its term loan debt. The new $13 million term loan has a lower interest rate of 12.4%, down from 15.9%, potentially saving $1.3 million in interest payments. The term loan's maturity date is extended to June 12, 2028. Additionally, the revolving credit facility's borrowing capacity has increased. These moves are part of Aytu's strategic focus on enhancing financial stability and growth.

The company reclassified most of its term loan from current to long-term liabilities, improving financial ratios. The warrant exercise resulted in 2,173,912 common shares being converted to 367,478 common shares and 1,806,434 pre-funded warrants. As of June 18, 2024, Aytu has 5,972,327 common shares outstanding.

Aytu BioPharma will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company, led by CEO Josh Disbrow, plans to host a webcasted fireside chat at 1:15pm ET and engage in one-on-one investor meetings. The event will be held virtually, and interested parties can access the webcast via the conference home page or directly through a provided link. The webcast will also be available for replay. To schedule a one-on-one meeting, investors should contact Lytham Partners or register on the event's website.

Aytu BioPharma, Inc. (NASDAQ:AYTU) will report its third-quarter fiscal 2024 financial and operational results on May 15, 2024. A conference call and webcast are scheduled for the same day at 4:30 p.m. Eastern Time to review the results.

Aytu BioPharma, Inc. announced its CEO, Josh Disbrow, will participate in the Emerging Growth Conference, presenting on April 4, 2024, at 4:40 p.m. Eastern time. The webcast will update attendees on the company's commercial progress.

Aytu BioPharma, Inc. reported Q2 2024 operating income of $2.4 million, net loss of $0.2 million, and adjusted EBITDA of $5.1 million. The Rx Segment net revenue was $18.7 million, with a net income of $0.7 million and adjusted EBITDA of $5.5 million. The ADHD Portfolio net revenue increased by 49% compared to Q2 2023. The company's cash balance was $19.5 million at December 31, 2023.

Aytu BioPharma, Inc. (AYTU) will report its financial and operational results for its second quarter of fiscal 2024 on February 14, 2024. The company has scheduled a conference call and webcast to review the results and conduct a question and answer section. Interested parties can access the conference call and webcast through provided call-in and webcast information. A teleconference replay of the call will also be available until February 28, 2024.

Aytu BioPharma, Inc. CEO, Josh Disbrow, will participate in a fireside chat and one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference on February 1, 2024. The webcasted fireside chat will be accessible on the company's website and can be replayed after the event. Management will also engage in virtual one-on-one meetings throughout the conference.